1. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
   Shikha Satendra Singh et al, 2015, World J Gastroenterol CrossRef
2. The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma
   Tasuku Matsuoka et al, 2014, Cancers CrossRef
3. Combining PI3K/Akt/mTOR Inhibition With Chemotherapy
   Albert A. De Vera et al, 2019 CrossRef
4. Therapeutic Potency of PI3K Pharmacological Inhibitors of Gastrointestinal Cancer
   Kamelia Hashemzadeh et al, 2018, Middle East J Dig Dis CrossRef
5. Genomic assays for Epstein–Barr virus-positive gastric adenocarcinoma
   Margaret L Gulley, 2015, Exp Mol Med CrossRef
6. SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway
   L-J Yuan et al, 2014, Cell Death Dis CrossRef
7. Gastric and Esophageal Cancers
   Armen Parsyan et al, 2014 CrossRef
8. Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer
   G. Roviello et al, 2019, Cancer Chemother Pharmacol CrossRef
9. Inhibition of Phosphatidylinositol 3-kinase (PI3K) Signaling Synergistically Potentiates Antitumor Efficacy of Paclitaxel and Overcomes Paclitaxel-Mediated Resistance in Cervical Cancer
   Jing Jing Liu et al, 2019, IJMS CrossRef
10. Oleanolic acid suppresses aerobic glycolysis in cancer cells by switching pyruvate kinase type M isoforms.
    Jia Liu et al, 2014, PLoS One CrossRef
11. Antagonism of miRNA-21 Sensitizes Human Gastric Cancer Cells to Paclitaxel
    Bo Jin et al, 2015, Cell Biochem Biophys CrossRef
12. Current and Future Therapies for Advanced Gastric Cancer
    Michael Davidson et al, 2015, Clinical Colorectal Cancer CrossRef
13. Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions
    Kate Young et al, 2016, Drugs CrossRef
14. Association between PIK3CA alteration and prognosis of gastric cancer patients: a meta-analysis.
    Hua Li et al, 0 CrossRef
15. Augmentation of Nab-Paclitaxel Chemotherapy Response by Mechanistically Diverse Antiangiogenic Agents in Preclinical Gastric Cancer Models
    Niranjan Awasthi et al, 2018, Mol Cancer Ther CrossRef
16. The PI3K/Akt/mTOR signaling pathway in gastric cancer; from oncogenic variations to the possibilities for pharmacologic interventions
    Ayda Baghery Saghchy Khorasani et al, 2021, European Journal of Pharmacology CrossRef
17. Targeted FGFR/VEGFR/PDGFR inhibition with dovitinib enhances the effects of nab-paclitaxel in preclinical gastric cancer models
    Kate Crawford et al, 2021, Cancer Biology & Therapy CrossRef
18. Evaluation of pH-Sensitive Polymeric Micelles Using Citraconic Amide Bonds for the Co-Delivery of Paclitaxel, Etoposide, and Rapamycin
    Min Jeong Jo et al, 2023, Pharmaceutics CrossRef
19. Phytochemicals and Nanoparticles in the Modulation of PI3K/Akt/mTOR Kinases and its Implications in the Development and Progression of Gastrointestinal Cancers: A Review of Preclinical and Clinical Evidence
    Arunaksharan Narayanankutty et al, 2023, PRA CrossRef
20. Senescence-related genes define prognosis, immune contexture, and pharmacological response in gastric cancer
    Xiaogang Shen et al, 2023, Aging CrossRef
21. Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety
    Md Sazzad Hassan et al, 2023, Biomedicines CrossRef
22. CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in PIK3CA-Mutant Gastric Cancer
    Lyla J. Stanland et al, 2023 CrossRef
23. Combination Therapy with a PI3K/mTOR Dual Inhibitor and Chloroquine Enhances Synergistic Apoptotic Cell Death in Epstein–Barr Virus-Infected Gastric Cancer Cells
    Mi-Young Kim et al, 2019, Molecules and Cells CrossRef
24. Carotenoids as modulators of the PI3K/Akt/mTOR pathway: innovative strategies in cancer therapy
    Biswajit Kumar Utpal et al, 2024, Med Oncol CrossRef